Skip to main content

Unfortunately we don't fully support your browser. If you have the option to, please upgrade to a newer version or use Mozilla Firefox, Microsoft Edge, Google Chrome, or Safari 14 or newer. If you are unable to, and need support, please send us your feedback.

We'd appreciate your feedback.Tell us what you think! opens in new tab/window

Elsevier
Publish with us
AI-Generated response:

What is the preferred treatment for pityriasis rosea?

Answer generated on June 4, 2024

The AI-generated responses are for illustration purposes only and should not be used for medical purposes.

The preferred treatment for pityriasis rosea is primarily symptomatic, including topical corticosteroids and oral antihistamines.

Consideration may be given to oral acyclovir for severe cases, especially if there is significant pruritus.[1-2]

  • Topical corticosteroids can be used to provide symptomatic relief from itching and inflammation.[1-2]

  • Oral antihistamines are recommended to help alleviate pruritus.[1-2]

  • Oral acyclovir, dosed at 400 mg three times daily for 7 days, can be considered for patients with severe symptoms, as it may help in attaining rash regression and lessening pruritus.[1][3]

  • Supportive treatments such as emollients, cornstarch baths, and menthol-containing lotions can be used to provide additional symptom relief.[1]

  • Phototherapy is another option for severe cases, although more studies are needed to fully establish its efficacy.[1]

Additional info

When treating pityriasis rosea, it's important to note that it is generally a self-limiting condition, often resolving without intervention within several weeks. The goal of treatment is primarily to manage symptoms and improve patient comfort. The use of acyclovir is based on evidence suggesting its effectiveness in reducing symptoms, particularly in severe cases, although it is not universally required for all patients. The decision to use systemic treatments like acyclovir should be balanced against potential side effects, including gastrointestinal disturbances and possible allergic reactions. Topical treatments and oral antihistamines are typically well-tolerated and can significantly alleviate discomfort associated with the rash. Phototherapy, while an option for severe cases, should be approached cautiously due to the lack of extensive evidence and the potential for skin damage with prolonged exposure. Always consider the individual patient's symptoms severity, potential side effects, and personal preferences when choosing the appropriate management strategy.

References

Reference 1

1.

Elsevier ClinicalKey Clinical Overview

Treatment Oral antihistamines Beware of drowsiness Hydroxyzine Hydrochloride Oral solution; Children 1 to 5 years weighing 40 kg or less: 50 mg/day PO in 3 to 4 divided doses as needed. Max: 2 mg/kg/day. Hydroxyzine Hydrochloride Oral tablet; Children and Adolescents 6 to 17 years: 50 to 100 mg/day PO in 3 to 4 divided doses as needed. Hydroxyzine Hydrochloride Oral tablet; Adults: 25 mg PO 3 to 4 times daily as needed. Acyclovir Acyclovir Oral tablet; Adults: 400 mg PO 3 times daily for 7 days. Pramoxine Hydrochloride 1% cream Pramoxine Hydrochloride Topical cream; Adults: Apply a thin layer topically to the affected skin area(s) 3 to 4 times daily as needed.

Treatment Cornstarch baths (224 g cornstarch in one-half tub of tepid water) to reduce pruritus Emollients or menthol-containing lotions to provide symptom relief

Treatment Topical steroids can be used for symptomatic relief; avoid corticosteroids that have systemic effects Consider acyclovir Phototherapy may be used for severe cases, although additional studies are needed Oral antihistamines, pramoxine hydrochloride 1% cream or lotion, emollients, and cornstarch baths may provide symptomatic relief A 2007 Cochrane Review failed to identify evidence supporting use of most therapies for treatment of pityriasis rosea 2019 Cochrane Review reported: One study demonstrated clearing in over 70% of patients treated with erythromycin This review did not include evidence from the use of acyclovir to treat pityriasis rosea When compared with placebo or no treatment, oral acyclovir probably leads to increased good or excellent medical practitioner–rated rash improvement; however, evidence for the effect of acyclovir on itch was inconclusive Low- to moderate-quality evidence suggests that erythromycin probably reduces itch more than placebo

Synopsis Pityriasis rosea is an acute, self-limited, benign exanthem that is typically on the trunk and proximal limbs; it is characterized by ovoid, raised plaques featuring a scaly collarette at lesion margins, typically starting with a herald patch and becoming more generalized Diagnosed by history and rash recognition on physical examination Initial lesion (herald patch) is usually 2 to 10 cm, ovoid, raised, mildly erythematous (light-skinned patients) plaque with a scaly collarette at margins More generalized rash with smaller, similar lesions that are pale or salmon-colored (lighter-skinned patients) or violet to dark gray (darker-skinned patients) erupt several days to a few weeks after herald patch; moderately pruritic Treatment is reassurance with possible use of oral antihistamines, pramoxine 1% cream or lotion, emollients, and cornstarch baths for symptom relief May also consider acyclovir for patients with severe pruritus Sun exposure can hasten resolution but may highlight hypopigmentation, especially in darker-skinned patients

Reference 2

2.

Lim, Henry W., Gelfand, Joel M. (2024). Eczemas, Photodermatoses, Papulosquamous (Including Fungal) Diseases, and Figurate Erythemas. In Goldman-Cecil Medicine (pp. 2701). DOI: 10.1016/B978-0-323-93038-3.00405-6

Treatment is primarily symptomatic, including topical corticosteroids and oral antihistamines.

Reference 3

3.

Chuh A, Zawar V, Sciallis G, Kempf W. Journal of the European Academy of Dermatology and Venereology : JEADV. 2016;30(10):1670-1681. doi:10.1111/jdv.13826.

Publish date: October 6, 2016.

Many clinical trials have been conducted on the treatment of pityriasis rosea (PR). Our aim was to establish a position statement for the management of adults with PR based on the best available evidence. We searched PubMed for all reports on randomized controlled trials for the treatment of PR published in the past 30 years. We retrieved 14 articles reporting randomized controlled trials, and found five which met our quality requirements for in-depth analyses. Erythromycin was found in a well-conducted triple-blind study to cast significant impacts on clinical outcomes. However, adverse gastrointestinal effects were fairly common. Another well-conducted study on azithromycin reported no significant benefit. It was reported in three well-conducted studies on oral acyclovir in low dose (400 mg three times daily for 7 days or 400 mg five times daily for 7 days) and high dose (800 mg five times daily for 7 days), that acyclovir is effective in attaining rash regression and lessening the pruritus. When compared against each other, the high-dose regimen demonstrated no benefit over the low-dose regimens. Our statement comprises the follows: (i) The diagnosis of PR should be ascertained; (ii) The patients should be assessed for rash severity and impacts on quality of life; (iii) PR is a self-limiting disease, and most patients do not necessitate any treatment; (iv) For patients necessitating active treatment, oral acyclovir as 400 mg three times daily for 7 days can be considered; (v) Attention should be given to adverse effects and contraindications of acyclovir; (vi) When PR occurs in early pregnancy, oral antiviral therapy could be considered after consulting experienced clinicians;

Follow up questions